HELP

Announcements

Nothing here yet

Daily updates

• Helus Pharma reported updated Phase 1/2a HLP003 data in major depressive disorder, including 12-month treatment outcomes, safety findings, and subjective psychedelic effects, and provided details on its ongoing Phase 3 PARADIGM trial.Sep 22, 2026

FDA designations

Nothing here yet

News

• Helus Pharma completes enrollment ahead of schedule in the Phase 3 APPROACH study of HLP003 for major depressive disorderJul 21, 2026
• Helus Pharma partnered with TARA Mind to advance veteran mental health programsApr 28, 2026
• Helus Pharma expressed support for the executive order advancing psychedelic research and regulatory pathways for serious mental health conditionsApr 20, 2026
• Helus Pharma announced topline Phase 2 results from a signal detection study of HLP004 in generalized anxiety disorderMar 5, 2026